A groundbreaking clause in a new deal between HHS and Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers' list prices.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
